Vivus has received approval from the US Food and Drug Administration (FDA) for its Qsymia as an adjunct to a reduced-calorie diet. Qsymia will be used to manage chronic weight in adult patients with an initial body mass index (BMI) of 30 ...
Pharmaceutical firm Merck has reported a 4% decline in its net sales in the third quarter 2012 to $11.5bn, as against $12.02bn for the same quarter in 2011. The firm's GAAP net income for the third quarter declined to $1.79bn, down from ...
Tags: Pharmaceutical firm Merck, Merck's pharmaceutical sales
Meda has announced that Orexo's Edluar, a sublingual formulation of zolpidem, gained regulatory approval in Europe. Edluar, which was developed by Orexo using its proprietary sublingual formulation technologies, is indicated for treatment ...
Tags: Regulatory Approval, approval of Edluar, commercial launch
Purdue Pharma has announced the availability of Intermezzo sublingual tablet CIV in 1.75mg and 3.5mg dosage strengths for insomnia characterized by middle-of-the-night awakenings followed by difficulty returning to sleep. ...
Tags: Purdue Pharma, Insomnia Drug, Intermezzo sublingual tablet CIV
Eisai has introduced the insomnia drug, Lunesta (eszopiclone), in Japan. Discovered and developed by Sunovion Pharmaceuticals, Lunesta is a non-benzodiazepine type GABAA agonist (non-benzodiazepine sedative hypnotic). In a Phase II/III ...
Fred Maxik wants to make a light bulb that will help you sleep. "Biological specific lights,” tuned so as not to interfere with an individual’s normal production of melatonin, the hormone secreted from the pineal gland linked to ...
Tags: market view, led
Fred Maxik wants to make a light bulb that will help you sleep. "Biological specific lights,” tuned so as not to interfere with an individual’s normal production of melatonin, the hormone secreted from the pineal gland ...
Tags: led